Core Viewpoint - Sensus Healthcare, Inc. reported significant growth in revenues and profitability for the third quarter of 2024, driven by increased sales of superficial radiotherapy (SRT) systems and strategic partnerships, including a notable agreement with Platinum Dermatology Partners [2][3][4]. Financial Performance - Revenues for Q3 2024 reached $8.8 million, a 127% increase from $3.9 million in Q3 2023, primarily due to higher SRT unit sales [2][4]. - Net income for Q3 2024 was $1.2 million, or $0.07 per diluted share, compared to a net loss of $1.5 million, or $0.09 per share, in the same quarter of 2023 [8][16]. - Adjusted EBITDA for Q3 2024 was $1.6 million, a turnaround from a negative $1.7 million in Q3 2023 [9][16]. Sales and Agreements - The company shipped 27 SRT systems in Q3 2024, up from 11 systems in Q3 2023, indicating strong demand [2][4]. - Sensus Healthcare signed a Fair Deal Agreement with Platinum Dermatology Partners, expanding access to SRT treatments across their network of 130 clinics [2][3][4]. Cost and Profitability - Cost of sales for Q3 2024 was $3.6 million, compared to $1.9 million in Q3 2023, reflecting the increased number of units sold [5][12]. - Gross profit for Q3 2024 was $5.2 million, representing 59.3% of revenues, compared to $2.0 million, or 51.0% of revenues, in Q3 2023 [5][12]. Cash Position - As of September 30, 2024, the company had $22.6 million in cash and cash equivalents, with no debt [10][28]. - Accounts receivable increased to $17.0 million, up from $10.6 million at the end of 2023, reflecting higher sales and extended payment terms with a large customer [10][28]. Market Outlook - The market for non-melanoma skin cancer treatments is substantial, with an estimated one in five Americans developing skin cancer in their lifetime, equating to approximately 70 million people [3][4]. - The company anticipates generating recurring revenue from the Fair Deal Agreements starting in 2025, as interest in SRT treatments continues to grow [3][4].

Company Performance - Sensus Healthcare, Inc. (SRTS) closed at $6.44, reflecting a +1.58% increase from the previous day, outperforming the S&P 500's gain of 0.22% [1] - The company has seen a 14.44% increase in share price over the past month, while the Medical sector has declined by 3.79% [1] - Upcoming earnings report is projected to show earnings of -$0.02 per share, indicating a year-over-year growth of 77.78%, with revenue expected at $5.84 million, up 49.74% from the prior year [1] Fiscal Year Estimates - Zacks Consensus Estimates for the fiscal year project earnings of $0.36 per share and revenue of $36.98 million, representing increases of +1100% and +51.51% respectively from the previous year [2] - Recent revisions to analyst forecasts are important as they reflect short-term business trends, with positive revisions indicating optimism about the company's outlook [2] Valuation and Industry Ranking - Sensus Healthcare, Inc. has a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 17.61, which is lower than the industry average of 26.83 [3] - The Medical - Instruments industry has a Zacks Industry Rank of 70, placing it in the top 28% of over 250 industries, suggesting strong performance potential [3]

Sensus Healthcare, Inc. (SRTS) ended the recent trading session at $5.90, demonstrating a +1.72% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.93%. At the same time, the Dow lost 0.41%, and the tech-heavy Nasdaq lost 1.53%. Prior to today's trading, shares of the company had lost 11.04% over the past month. This has lagged the Medical sector's loss of 3.08% and the S&P 500's gain of 2.17% in that time. The upcoming earnings release of Sensus Healthcare, Inc. ...

Sensus Healthcare, Inc. (SRTS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $5.80, moving -1.86% from the previous trading session. This change lagged the S&P 500's 0.19% loss on the day. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%. The company's stock has dropped by 12.83% in the past month, falling short of the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%. Analysts and investors alike will be keeping a close eye on the performance of Sensus Healthcare, Inc. in it ...

Company Overview - Sensus Healthcare, Inc. (SRTS) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Performance Metrics - Over the past week, SRTS shares increased by 1.54%, slightly outperforming the Zacks Medical - Instruments industry, which rose by 1.53% [6] - In the last month, SRTS shares rose by 3.36%, significantly better than the industry's performance of 0.98% [6] - For a longer-term perspective, SRTS shares have appreciated by 6.6% over the past quarter and an impressive 107.72% over the last year, compared to the S&P 500's gains of 6.49% and 25.94%, respectively [7] Trading Volume - The average 20-day trading volume for SRTS is 257,456 shares, which serves as a useful indicator of market interest and price movement [8] Earnings Outlook - Recent earnings estimate revisions for SRTS show one upward revision for the full year, increasing the consensus estimate from $0.29 to $0.36 over the past 60 days [10] - For the next fiscal year, there has been one upward revision with no downward revisions during the same period, indicating positive earnings momentum [10]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Sensus Healthcare, Inc. (SRTS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Sensus Healthcare, Inc. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank in ...

Shares of Sensus Healthcare, Inc. (SRTS) have gained 1.1% over the past four weeks to close the last trading session at $6.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.67 indicates a potential upside of 65.7%. The average comprises three short-term price targets ranging from a low of $10 to a high of $12, with a standard deviation of $1.15. While the lowest estimate i ...

Slavica/E+ via Getty Images Investment Thesis Sensus Healthcare (NASDAQ:NASDAQ:SRTS) is a company that offers equipment to treat skin problems, including non-melanoma cancer. These products have shown strong demand, but are usually affected during economically unstable periods such as 2020 and 2023, causing years as bad as the previous one. During 2024 the company has been recovering and management has begun exciting initiatives to create recurring revenue streams to provide more stability and also recently ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Sensus Healthcare, Inc. (SRTS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Sensus Healthcare, Inc. is one of 1019 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank conside ...